This company has been acquired
ZYNE Stock Overview
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Zynerba Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.25 |
| Beta | 1.19 |
| 1 Month Change | -1.52% |
| 3 Month Change | 282.24% |
| 1 Year Change | 96.08% |
| 3 Year Change | -65.79% |
| 5 Year Change | -82.17% |
| Change since IPO | -92.00% |
Recent News & Updates
Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29Shareholder Returns
| ZYNE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.0% | -2.5% | 1.4% |
| 1Y | 96.1% | -3.5% | 22.2% |
Return vs Industry: ZYNE exceeded the US Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: ZYNE exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| ZYNE volatility | |
|---|---|
| ZYNE Average Weekly Movement | 84.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZYNE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZYNE's weekly volatility has increased from 43% to 84% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 26 | Armando Anido | www.zynerba.com |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.
Zynerba Pharmaceuticals, Inc. Fundamentals Summary
| ZYNE fundamental statistics | |
|---|---|
| Market cap | US$65.60m |
| Earnings (TTM) | -US$37.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs ZYNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYNE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.58m |
| Earnings | -US$37.58m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZYNE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/12 00:50 |
| End of Day Share Price | 2023/10/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zynerba Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Corey Davis | Canaccord Genuity |
| Elemer Piros | Cantor Fitzgerald & Co. |
| Oren Livnat | H.C. Wainwright & Co. |